Objective:To explore the diagnostic value of the serum CA125, G-17, and plasma D-D, M2-PK in patients with gastric cancer.Methods:A total of 70 patients with gastric cancer who were treated in our Hospital from September 2016 to September 2017 were selected as observation group, 45 patients with benign gastric disorders treated in the same period as disease control group, and 45 normal volunteers as health control group. The level and positive rate of serum CA125, G-17, and plasma D-D, M2-PK were compared between the three groups, and the diagnostic efficency of CA125, G-17, D-D and M2-PK for gastric cancer was observed.Results:Serum CA125, G-17, and plasma D-D, M2-PK level were significantly higher in the observation group than thetwo control groups(P<0.05). The levels of CA125, G-17, D-D and M2-PK in different clinical stages were statistically significant(P<0.05). The positive rate of CA125, G-17, D-D and M2-PK were significantly higher in the observation group than that in the two control groups(P<0.05). The sensitivity of combined detection of serum CA125,G-17 and plasma D-D, XM2-PK was significantly higher than that of each alone(P<0.05); however, there was no significant difference in the positive rate between the healthy control group and the disease control group(P>0.05). The specificity of joint detection was lower than each detection alone; when compared with D-D, M2-PK, the difference were statistically significant(P<0.05).Conclusion:Serum CA125,G-17 and plasma D-DX M2-PK have high application value in early diagnosis of gastric cancer, and combined detection of four indexes can significantly improve the sensitivity of diagnosis and avoid missed diagnosis and misdiagnosis to a certain extent. It has important value for early detection of gastric cancer. |
[1] 邹文斌,李兆申.中国胃癌发病率及死亡率研究进展[J].中国实用内科杂志,2014,34(4):408-415.
[2] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3] 宋杰,陈凤格,赵伟,等.胃癌的发病率现状与治疗研究进展[J].中国慢性病预防与控制,2016,24(9):704-707.
[4] 于嘉伟,袁洪新,马利林,等.CHPPC联合静脉化疗对老年胃癌患者肿瘤标志物含量及免疫功能的影响[J].东南大学学报:医学版,2017,36(3):439-443.
[5] 何永亮,王琦玲,成永莲,等.胃癌STAT3、Survivin和RegⅣ的表达及其与临床病理参数间的相关性[J].现代医学,2017,45(2):224-229.
[6] 马丽华,钱屹崟,吴剑平,等.D-二聚体和肿瘤标记物在胃癌诊断中的价值[J].江苏医药,2014,40(17):2019-2021.
[7] 中华人民共和国卫生部医政司.胃癌诊疗规范(2011年版)[J].中国医学前沿杂志:电子版,2012,4(5):62-71.
[8] 王沁易,张煦.BTG1蛋白在胃癌中的表达水平及临床意义[J].空军医学杂志,2016,32(3):171-174.
[9] 蔡懿婷,许慈,董晴晴,等.KIAA1199基因重组慢病毒载体的构建及在人胃肿瘤细胞MKN28中的表达[J].解剖学研究,2016,38(5):375-379.
[10] 徐巧玲,尤徐阳,吴娜静,等.临床病理学分析结合CEA、CA19-9与CA125检测对诊断胃癌术后腹膜转移的意义[J].标记免疫分析与临床,2016,23(11):1321-1326.
[11] 梁勇,熊清泉,崇杨,等.胃癌组织趋化因子受体CXCR4的表达及其临床意义[J].江苏大学学报:医学版,2017,27(3):252-256.
[12] 严波,杨善峰,李祥,等.血清胃泌素17、胸苷激酶1联合检测辅助诊断胃癌的价值[J].山东医药,2016,56(8):40-41.
[13] 郭飞波,杨勇.果糖-1,6-二磷酸酶在胃癌组织中的表达及其对预后的预测价值[J].现代医学,2017,45(3):334-339.
[14] 许慈,蔡懿婷,董晴晴,等.RNA干扰抑制磷脂酰肌醇3-激酶p110β的表达增加氟尿嘧啶诱导人胃癌细胞凋亡的能力[J].解剖学研究,2016,38(1):1-6. |